Eyenovia (NASDAQ:EYEN) Earns Neutral Rating from HC Wainwright

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $2.00 price target on the stock. HC Wainwright’s target price would indicate a potential downside of 15.97% from the stock’s current price.

Other analysts have also recently issued reports about the company. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th.

Eyenovia Trading Down 12.8 %

NASDAQ EYEN opened at $2.38 on Thursday. Eyenovia has a 12 month low of $2.22 and a 12 month high of $205.60. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average of $6.78 and a 200-day moving average of $33.51. The company has a market cap of $265.20 million, a PE ratio of -3.26 and a beta of 1.25.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($8.80) EPS for the quarter, beating analysts’ consensus estimates of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the company earned ($14.40) earnings per share. On average, equities research analysts anticipate that Eyenovia will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyenovia

Several institutional investors and hedge funds have recently made changes to their positions in the company. Financial Management Network Inc. bought a new stake in Eyenovia in the 3rd quarter valued at $39,000. Nations Financial Group Inc. IA ADV boosted its position in shares of Eyenovia by 78.6% in the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after acquiring an additional 40,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after acquiring an additional 149,471 shares in the last quarter. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.